曲妥珠单抗联合新辅助化疗治疗HER2阳性乳腺癌的临床疗效及对患者生存质量的影响  

Clinical efficacy of trastuzumab combined with neoadjuvant chemotherapy for HER2-positive breast cancer and the impact on quality of life of patients

作　　者：董懿[1] 王钢乐[1] 曹技磊 DONG Yi;WANG Gangle;CAO Jilei(Department of Breast,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京妇产医院乳腺科

出　　处：《癌症进展》2019年第19期2299-2301,共3页Oncology Progress

摘　　要：目的探讨曲妥珠单抗联合新辅助化疗治疗人表皮生长因子受体2(HER2)阳性乳腺癌的临床疗效及对患者生存质量的影响。方法采用抽签法随机将30例HER2阳性女性乳腺癌患者分为对照组和观察组,每组15例。对照组患者术前接受新辅助化疗,观察组患者术前接受曲妥珠单抗联合新辅助化疗,比较两组患者的临床疗效、治疗前后的肿瘤相关炎性因子[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)]水平以及治疗前和治疗后8个月的生存质量。结果观察组患者的总有效率为86.67%(13/15),高于对照组患者的53.33%(8/15),差异有统计学意义(P﹤0.05)。治疗前,两组患者的血清IL-6、IL-8、TNF-α、IL-1β水平比较,差异均无统计学意义(P﹥0.05);治疗后,观察组患者的血清IL-6、IL-8、TNF-α、IL-1β水平均明显低于对照组患者,差异均有统计学意义(P﹤0.01)。治疗前,两组患者的生存质量评分比较,差异无统计学意义(P﹥0.05);治疗后8个月,观察组患者的生存质量评分明显高于对照组患者,差异有统计学意义(P﹤0.01)。结论与术前单纯新辅助化疗相比,术前曲妥珠单抗联合新辅助化疗治疗HER2阳性乳腺癌可获得更好的临床疗效,且可有效改善患者的生存质量。Objective To evaluate the clinical efficacy of trastuzumab combined with neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer and the impact on patients' quality of life (QOL).Method A total of 30 case with HER2 positive breast cancer were randomized as control group and study group using a lottery-based technique,and each group had 15 cases.The control group received preoperative neoadjuvant chemotherapy,and the study group had trastuzumab combined with neoadjuvant chemotherapy before surgery, the clinical effect,and expression levels of tumor-associated inflammatory factors [interleukin-6 (IL-6),interleukin- 8 (IL-8),tumor necrosis factor-α(TNF-α),and interleukin-1β(IL-1β)] before and after treatment,as well as the QOL before surgery and 8 months after surgery in the two groups were compared.Result The overall response rate in study group was 86.67%(13/15),which was significantly higher than the 53.33%(8/15) in control group,and the difference was of statistical significance (P<0.05).Before treatment,there was no significant difference in respect of the serum IL-6, IL-8,TNF-α and IL-1β levels between the two groups (P>0.05);while after treatment,the serum IL-6,IL-8,TNF-α and IL-1β levels in study group were significantly reduced compared to control group (P<0.01).The QOL scores were of no significant difference between the two groups before treatment (P>0.05),and were evidently improved in study group compared to control group in 8 months after treatment (P<0.01).Conclusion The combination of trastuzumab and neoadjuvant chemotherapy for breast cancer patients before surgery would provide better clinical efficacy than preoperative neoadjuvant chemotherapy alone,and may also improve the QOL of patients.

关 键 词：乳腺癌 曲妥珠单抗 新辅助化疗 肿瘤相关炎性因子 HER2 生存质量 

分 类 号：R737.9[医药卫生—肿瘤]